Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus CHLOROTHIAZIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus CHLOROTHIAZIDE SODIUM.
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE vs CHLOROTHIAZIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
Initial dose: 1 tablet (candesartan cilexetil 16 mg / hydrochlorothiazide 12.5 mg) orally once daily; titrate based on response to maximum dose of 32 mg/25 mg once daily.
500 mg to 1 g orally or intravenously once or twice daily.
None Documented
None Documented
Candesartan: ~9 hours (terminal); Hydrochlorothiazide: 6–15 hours (terminal). Both support once-daily dosing.
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Candesartan: 33% renal, 67% biliary/fecal. Hydrochlorothiazide: ≥95% renal (unchanged).
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic